All In Biotech

Drug Trial Radar · NCT03631199

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 673 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

673

Actual

Start

Dec 21, 2018

Primary completion

Aug 9, 2021

Study completion Jan 26, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • canakinumabDrug

    canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)

  • canakinumab-matching placeboDrug

    canakinumab placebo every 3 weeks (squamous and non-squamous)

  • pembrolizumabDrug

    200 mg every 3 weeks (squamous and non-squamous)

  • carboplatinDrug

    Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)

  • cisplatinDrug

    75 mg/m\^2 every 3 weeks (non-squamous)

  • paclitaxelDrug

    200 mg/m\^2 every 3 weeks (squamous)

  • nab-paclitaxelDrug

    100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)

  • pemetrexedDrug

    500 mg/m\^2 every 3 weeks (non-squamous)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Safety Run-in): Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: During the first 42 days of dosing
  2. Part 2 (Double-blind, Randomized, Placebo-controlled): Progression-free Survival (PFS) Per Investigator Assessment Using RECIST v1.1Time frame: 18 months
  3. Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Survival (OS) Per Investigator Assessment Using RECIST v1.1Time frame: Up to approximately 32 months

Locations

152 sites in 41 countries. Site status is shown where the registry gives one.

  • Pacific Shores Medical Group

    Long Beach, California

  • USC Kenneth Norris Comprehensive Cancer Center

    Los Angeles, California

  • AdventHealth

    Orlando, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Wooloongabba, Queensland, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Murdoch, Western Australia, Australia

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Linz, Upper Austria, Austria

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Brampton, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Temuco, Araucania, Chile

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Changchun, Jilin, China

  • Novartis Investigative Site

    Xi’an, Shanxi, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Valledupar, Cesar Department, Colombia

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Ostrava, Vitkovice, Czechia

  • Novartis Investigative Site

    Herning, Denmark

  • Novartis Investigative Site

    Oulu, Finland

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Marseille, Bouches Du Rhone, France

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.